News Image

Why the dividend investor may take a look at NASDAQ:SNY.

By Mill Chart

Last update: Feb 14, 2024

Our stock screener has spotted SANOFI-ADR (NASDAQ:SNY) as a good dividend stock with solid fundamentals. NASDAQ:SNY shows decent health and profitability. At the same time it gives a good and sustainable dividend. We'll dive into each aspect below.

What does the Dividend looks like for NASDAQ:SNY

To gauge a stock's dividend quality, ChartMill utilizes a Dividend Rating ranging from 0 to 10. This comprehensive assessment considers various dividend aspects, including yield, history, growth, and sustainability. NASDAQ:SNY has achieved a 8 out of 10:

  • With a Yearly Dividend Yield of 4.15%, SNY is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 4.43, SNY pays a better dividend. On top of this SNY pays more dividend than 95.54% of the companies listed in the same industry.
  • SNY's Dividend Yield is rather good when compared to the S&P500 average which is at 2.49.
  • SNY has been paying a dividend for at least 10 years, so it has a reliable track record.
  • SNY pays out 35.10% of its income as dividend. This is a sustainable payout ratio.
  • SNY's earnings are growing more than its dividend. This makes the dividend growth sustainable.

Health Analysis for NASDAQ:SNY

ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:SNY, the assigned 5 for health provides valuable insights:

  • SNY has an Altman-Z score of 3.06. This indicates that SNY is financially healthy and has little risk of bankruptcy at the moment.
  • SNY has a better Altman-Z score (3.06) than 77.72% of its industry peers.
  • SNY has a debt to FCF ratio of 2.59. This is a good value and a sign of high solvency as SNY would need 2.59 years to pay back of all of its debts.
  • The Debt to FCF ratio of SNY (2.59) is better than 91.09% of its industry peers.
  • A Debt/Equity ratio of 0.22 indicates that SNY is not too dependend on debt financing.

Evaluating Profitability: NASDAQ:SNY

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:SNY, the assigned 7 is noteworthy for profitability:

  • SNY has a better Return On Assets (10.12%) than 94.06% of its industry peers.
  • The Return On Equity of SNY (17.47%) is better than 92.08% of its industry peers.
  • SNY has a Return On Invested Capital of 15.53%. This is amongst the best in the industry. SNY outperforms 92.57% of its industry peers.
  • The 3 year average ROIC (6.95%) for SNY is below the current ROIC(15.53%), indicating increased profibility in the last year.
  • With an excellent Profit Margin value of 18.09%, SNY belongs to the best of the industry, outperforming 93.56% of the companies in the same industry.
  • SNY has a Operating Margin of 27.75%. This is amongst the best in the industry. SNY outperforms 94.06% of its industry peers.
  • SNY's Operating Margin has improved in the last couple of years.
  • SNY has a Gross Margin of 70.31%. This is in the better half of the industry: SNY outperforms 78.22% of its industry peers.

More Best Dividend stocks can be found in our Best Dividend screener.

Our latest full fundamental report of SNY contains the most current fundamental analsysis.

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

SANOFI-ADR

NASDAQ:SNY (4/19/2024, 7:16:58 PM)

After market: 46.3 0 (0%)

46.3

+0.91 (+2%)

SNY News

News Image9 days ago - InvestorPlaceThe $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today

Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.

News Image12 days ago - InvestorPlaceWhy Is Auddia (AUUD) Stock Up 192% Today?

Auddia stock is taking off on Monday with heavy trading of AUUD stock after the company received a new AI tech patent.

News Image12 days ago - InvestorPlaceAIRC Stock Alert: Blackstone Is Taking Apartment Income REIT Private

Apartment Income REIT stock is rising higher on Monday as investors in AIRC shares react to a deal to take the company private.

News Image12 days ago - InvestorPlaceSanofi Layoffs 2024: What to Know About the Latest SNY Job Cuts

Sanofi layoffs are coming for the company's R&D employees and it makes major changes to how it handles development going forward.

News Image24 days ago - Market News VideoFirst Week of May 17th Options Trading For Sanofi (SNY)
News Image26 days ago - Market News VideoFirst Week of September 20th Options Trading For Sanofi (SNY)
News Imagea month ago - InvestorPlaceTo the Moon and Beyond: 7 Stocks With Cosmic Potential

With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential.

News Imagea month ago - InvestorPlacePassport to Profits: 7 Global Growth Gems to Diversify Your Holdings

With certain sectors in the domestic market appearing overstretched, these global growth stocks may offer better opportunities.

News Image2 months ago - InvestorPlaceBiotechs on the Rise: 3 Stocks to Buy for a Shot of Profits

Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.

SNY Links
Follow us for more